Keywords: amylin, 3rd-qtr, net, loss, narrows, 8m, usa
Amylin's 3rd-qtr net loss narrows to $39.8M
Article | 29 October 2007
The USA's Amylin Pharmaceuticals net loss for the quarter ended September 30, 2007, was $39.8 million, or $0.30 per share, versus $46.1 million, or $0.36 per ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
